Transcriptional regulatory mechanisms of the human apolipoprotein genes in vitro and in vivo

Current Opinion in Lipidology

Volumn 12, Issue 2, 2001, Pages 181-207

  Zannis, Vassilis I ^a,b,c   Kan, Horng Yuan ^a,b,c   Kritis, Aristidis ^a,b,c   Zanni, Eleni E ^a,b,c   Kardassis, Dimitris ^a,b,c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CRETE   (Greece)

^c DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; GENETIC TRANSCRIPTION; HEART PROTECTION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; REGULATORY MECHANISM; TRANSCRIPTION REGULATION;

EID: 0035081596     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/00041433-200104000-00012     Document Type: Article

References (110)

1. Transcriptional regulation of the genes involved in lipoprotein transport. The role of proximal promoters and long range regulatory elements and factors in apolipoprotein gene region
2. Common themes in assembly and function of eukaryotic transcription complexes
3. The general transcription factors of RNA polymerase II
4. TAFs revisited: More data reveal new twists and confirm old ideas
5. The RNA polymerase II holoenzyme and its implications for gene regulation
6. Genetics of transcriptional regulation in yeast: Connections to the RNA polymerase II CTD
7. SWI/SNF2 and related proteins: ATP-driven motors that disrupt protein-DNA interactions?
8. The Swi/Snf family nucleosome-remodeling complexes and transcriptional control
9. Histone acetylation and transcriptional regulatory mechanisms
10. The many HATs of transcription coactivators
11. Acetylation regulates transcription factor activity at multiple levels
12. Gene activation by recruitment of the RNA polymerase II holoenzyme
13. Hepatocyte nuclear factor 4 (HNF4)
14. Hepatocyte nuclear factor 3/forkhead protein family: Mammalian transcription factors that possess divergent cellular expression patterns and binding specificities
15. CCAAT/enhancer binding proteins (C/EBP)
16. Hepatocyte nuclear factor 1 (HNF1) and liver gene expression
17. Nuclear receptors spring into action
18. Nuclear receptors: Coactivators, corepressors and chromatin remodeling in the control of transcription
19. Purification and biochemical characterization of the promoter-specific transcription factor, SP1
20. Interaction of a gene-specific transcription factor with the adenovirus major late promoter upstream of the TATA box region
21. Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. II. Purification and characterization
22. SREBP-2, a second basic-helix-loop-helixleucine zipper protein that stimulates transcription by binding to a sterol regulatory element
23. Genetic mutations affecting human lipoproteins, their receptors and their enzymes
24. Intracellular modification of human apolipoprotein All (apoA-II) and sites of apoA-II mRNA synthesis: Comparison of apoA-II with apoCIII and apoCIII isoproteins
25. Promoter elements and factors required for hepatic transcription of the human apoA-II gene
26. Transcriptional regulation of the human apolipoprotein genes
27. Regulation of the human apoA-II gene by the synergistic action of factors binding to the proximal and distal regulatory elements
28. Cooperative binding of upstream stimulatory factor and hepatic nuclear factor 4 drives the transcription of the human apolipoprotein A-II gene
29. SREBP-1 binds to multiple sites and transactivates the human apoA-II promoter in vitro: SREBP-1 mutants defective in DNA binding or transcriptional activation repress the apoA-II promoter activity
30. DNA binding specificity and transactivation properties of SREBP-2 bound to multiple sites on the human apoA-II promoter
31. Retinoids increase human apolipoprotein A-II expression through activation of the retinoid X receptor but not the retinoic acid receptor
32. Ultraspiracle, a Drosophila retinoic X receptor α homologue, can mobilize the human thyroid hormone receptor to transactivate a human promoter
33. The -911/+29 sequence of human apolipoproteln A-II promoter is sufficient to confer liver restricted expression, developmental changes and response to a high fat diet in transgenic mice
34. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor
35. The complete sequence and structural analysis of human apolipoprotein B-100: Relationship between apoB-100 and apoB-48 forms
36. Organization of the regulatory elements and nuclear activities participating in the transcriptional activation of the human apoB gene
37. The mechanism by the human apolipoprotein B gene reducer operates involves blocking of transcriptional activation by hepatocyte nuclear factor 3
38. Sequences containing the secondintron enhancer are essential for transcription of the human apoB gene in the livers of transgenic mice
39. Apolipoprotein B gene expression in a series of human apolipoprotein B transgenic mice generated with recAassisted restriction endonuclease cleavage-modified bacterial artificial chromosomes
40. Identification and characterization of a 315-base pair enhancer, located more than 55 kilobases 5' of the apolipoprotein B gene, that confers expression in the intestine
41. Complex interactions between SP1 bound to multiple distal regulatory sites and HNF-4 bound to the proximal promoter lead to transcriptional activation of liver-specific human apoCIII gene
42. Distal apoCIII regulatory elements F to J act as a general modular enhancer for proximal promoters that contain hormone response elements: Synergism between HNF-4 molecules bound to the proximal promoter and distal enhancer sites
43. Binding specificity and modulation of the human apoCIII promoter activity by heterodimers of ligand-dependent nuclear receptors
44. Transcriptional regulation of the apolipoprotein A-IV gene involves synergism between a proximal hormone response element and a distant enhancer located in the upstream promoter region of the apolipoprotein C-III gene
45. Distribution of apoA-I, apoCII, apoCIII and apoE mRNA in human tissues, time-dependent induction of apoE mRNA by cultures of human monocyte-macrophages
46. Promoter elements and factors required for hepatic and intestinal transcription of the human apoCIII gene
47. Intestinal apolipoprotein AI gene transcription is regulated by multiple distinct DNA elements and is synergistically activated by the orphan nuclear receptor, hepatocyte nuclear factor 4
48. Retinoids increase human apoCIII expression at the transcriptional level via the retinoid X receptor. Contribution to the hypertriglyceridemia action of retinoids
49. Promoter elements and factors involved in hepatic transcription of the human apoA-I gene positive and negative regulators bind to overlapping sites
50. Binding specificity and modulation of the apoA-I promoter activity by homo- and heterodimers of nuclear receptors
51. NFY transcription factor binds to regulatory element AIC and transactivates the human apolipoprotein A-I promoter in HepG2 cells
52. High levels of human apolipoprotein A-I in transgenic mice result in increased plasma levels of small HDL particles comparable to human HDL
53. Structure, evolution and tissue-specific synthesis of human apolipoprotein A-IV
54. The apolipoprotein A-I/C-III/A-IV gene cluster: ApoC-III and apoA-IV expression is regulated by two common enhancers
55. A hormone response element in the human apoCIII enhancer is essential for intestinal expression of the apoA-I and apoCIII genes and contributes to the hepatic expression of the two linked genes in transgenic mice
56. Overexpression of human apolipoprotein C-III in transgenic mice results in an accumulation of apolipoprotein B48 remnants that is corrected by excess apolipoprotein E*
57. Characterization of an enhancer element in the human apolipoprotein CIII gene that regulates human apolipoprotein A-I gene expression in the intestinal epithelium
58. Tissue-specific expression of the human apolipoprotein A-IV gene in transgenic mice [abstract]
59. The -700/-310 fragment of the apolipoprotein A-IV gene combined with the -890/-500 apolipoprotein CIII enhancer is sufficient to direct a pattern of gene expression similar to that for the endogenous apolipoprotein A-IV gene
60. Expression of human apolipoprotein A-I/CIII/A-IV gene cluster in mice induces hyperlipidemia but reduces atherogenesis
61. Developmental and pharmacological regulation of apolipoprotein CII gene expression. Comparison with apoCI and apoCIII gene regulation
62. 3-Hydroxy-3methylglutaryl CoA reductase inhibitors reduce serum triglyceride levels through modulation of apolipoprotein CIII and lipoprotein lipase
63. Mammalian hepatocyte differentiation requires the transcription factor HNF-4α
64. Utilization of recombinant adenovirus and dominant negative mutants to characterize hepatocyte nuclear factor 4-regulated apolipoprotein AI and CIII expression
65. Beneficial effects of fibrates on apolipoprotein A-I metabolism occur independently of any peroxisome proliferative response
66. Regulation of apoA-I gene expression by fibrates
67. The nuclear receptors peroxisome proliferator-activated receptor α and Rev-erbα mediate the species-specific regulation of apolipoprotein A-I expression by fibrates
68. Alterations in lipoprotein metabolism in peroxisome proliferator-activated receptor α-deficient mice
69. Hepatocyte-specific mutation establishes retinoid X receptor α as a heterodimeric integrator of multiple physiological processes in the liver
70. Transcriptional regulation of apolipoprotein A-I gene expression by the nuclear receptor RORα
71. The full induction of human apoprotein A-I gene expression by the experimental nephritic syndrome in transgenic mice depends on cis-acting elements in the proximal 256 base-pair promoter region and the trans-acting factor early growth response factor
72. Elevated hepatic apolipoprotein A-I transcription is associated with diet-induced hyperalphalipoproteinemia in rabbits
73. The SP1 sites of the human apoCIII enhancer are essential for the expression of the apoCIII gene and contribute to the hepatic and intestinal expression of the apoA-I gene in transgenic mice
74. Direct physical interactions between SP1 and HNF-4 mediates synergistic transactivation of the apolipoprotein CIII promoter
75. Transactivation of the ApoCIII promoter by ATF-2 and repression by members of the Jun family
76. Activation of CAAT enhancer-binding protein δ (C/EBPδ) by interleukin-1 negatively influences apolipoprorein CIII expression
77. Repression of apoC-III gene expression by TNFα involves C/EBPdelta/NF-IL6β via an IL-1 independent pathway
78. TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways
79. IB kinase-β: NF-β activation and complex formation with IB kinase-α and NIK
80. The stress-activated protein kinase pathways
81. Mitogen-activated protein kinase regulates transcription of the apoCIII gene. Involvement of the orphan nuclear receptor HNF4
82. SMAD proteins transactivate the human apoCIII promoter by physically and functionally interacting with hepatocyte nuclear factor-4
83. Plus and minus RNAs of peach latent mosaic viroid self-cleave in vivo via hammerhead structures
84. Identification and functional characterization of a Smad binding element (SBE) in the JunB promoter that acts as a transforming growth factor-beta, activin, and bone morphogenetic protein-inducible enhancer
85. TGF-β signaling from cell membrane to nucleus through SMAD proteins
86. Regulation of Smad signaling by protein associations and signaling crosstalk
87. Estradiol stimulates apolipoprotein A-I but not A-II-containing particle synthesis and secretion by stimulating mRNA transcription rate in HepG2 cells
88. Estrogen increases apolipoprotein (apo) A-I secretion 4X in HepG2 cells by modulating transcription of the - 256/ +397 apoA-I gene promoter
89. Estrogen regulation of the apolipoprotein AI gene promoter through transcription cofactor sharing
90. Regulation of human apolipoprotein A-I gene expression by gramoxone.Use of antioxidant response element ARE X to Y
91. Expression of apolipoprotein E during nerve degeneration and regeneration
92. Apolipoprotein E associated with astrocylic gila of the central nervous system and with non-myelinating gila of the peripheral nervous system
93. Apolipoprotein E (ApoE), a Bmp-2 (bone morphogenic protein) upregulated gene in mesenchymal progenitors (C3H10T1/2), is highly expressed in murine embryonic development
94. Astrocytes and microglia respond to estrogen with increased apoE mRNA in vivo and in vitro
95. Identification and characterization of a new human gene (apoC4) in the apolipoprotein E, C-I and C-II gene locus
96. A far-downstream hepatocyte-specific control region directs expression of the Inked human apolipoprotein E and CI genes in transgenic mice
97. Expression of the human apolipoprotein E gene is regulated by multiple positive and negative elements
98. Characterization of a human apolipoprotein E gene enhancer element and its associated protein factors
99. In vivo footprinting analysis of the hepatic control region of human apolipoprotein E/C-I/C-IV/C-II gene locus
100. Multiple tissue-specific elements control the apolipoprotein E/C-I gene locus in transgenic mice
101. Structure of the hepatic control region of the human apolipoprotein E/C-I gene locus
102. Evolutionary duplication of a hepatic control region in the human apolipoprotein E gene locus
103. Two hepatic enhancers, HCR.1 and HCR.2, coordinate the liver expression of the entire human apolipoprotein E/C-I/C-IV/ C-II gene cluster
104. Duplicated downstream enhancers control expression of the human apolipoprotein E gene in macrophages and adipose tissue
105. Expanding the Transfac database towards an expert system of regulatory molecular mechanisms
106. A short proximal promoter and the distal hepatic control region-1 (HCR-1) contribute to the liver-specific expression of the human apoCII gene in vitro. Tissue specific enhancement by HCR-1 requires two proximal hormone response elements which have different binding specificities for orphan receptors HNF-4, ARP-1 and EAR-2
107. Transactivation of the human apoCII promoter by orphan and ligand-dependent nuclear receptors. The regulatory element CIIC is a thyroid hormone response element
108. Cloning and sequencing of PYBP, a pyrimidine-rich specific single strand DNA binding protein
109. HMG-D is an architecture-specific protein that preferentially binds to DNA containing the di-nucleotide TG
110. The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures